OTTAWA, June 26, 2018 /CNW/ - The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug UtilizationInformation System (NPDUIS) research initiative, today published the second annual edition of Meds Entry Watch.
The report series, which provides the latest information on new drugs launched in Canada
Important new drugs have been launched since 2009, accounting for nearly one quarter of brand-name drug sales in Canada by 2016. In line with trends observed from 2009 to 2014, the study found that high-priced speciality drugs such as those used to treat rare diseases, biologic drugs and oncology drugs, continue to dominate the new drug landscape in 2015 and 2016, both in Canada and internationally. The report also found that while Canada launched more new drugs than most OECD countries, it launched fewer than all PMPRB comparator countries, including many with lower average patented drug prices.
Meds Entry Watch is available on the PMPRB website in PDF and accessible HTML formats.
The next edition of this publication will continue to build on this analysis and provide further insight into the drugs introduced in 2016, along with an analysis of the drugs launched in 2017.
Follow us on Twitter: @PMPRB_CEPMB
SOURCE Patented Medicine Prices Review Board
Subscribe to our Free Newsletters!